Gynesonics Announces Brigham and Women’s Faulkner Hospital Becomes the First in Massachusetts to Offer Innovative New Procedure to Treat Symptomatic Uterine Fibroids

gynesonics

Sonata Treatment provides patients with an incision-free, outpatient option with exceptional results and fast recovery

Redwood City, Calif. – September 3, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Brigham and Women’s Faulkner Hospital is the first provider in Massachusetts to offer the Sonata® System as a treatment for symptomatic uterine fibroids.  Fibroids are benign growths in or around the uterus, with about 70 percent of white women and more than 80 percent of black women having uterine fibroids before the age of 50.  Uterine fibroids may cause significant and debilitating symptoms, including heavy menstrual bleeding.  Symptoms may worsen over time if fibroids are left untreated, which leads to more than two million women in the U.S. undergoing treatment for uterine fibroids each year.

“Our goal at Brigham and Women’s Faulkner Hospital is to be able to offer our patients with symptomatic fibroids as many treatments options as possible so that we can match the appropriate patient to the appropriate intervention,” said James A. Greenberg, M.D., Chief of Gynecology, Brigham and Women’s Faulkner Hospital and Associate Professor, Harvard Medical School.  “The introduction of transcervical RF myoma ablation is an exciting and essential addition to our toolkit.  For the first time, the Sonata System allows us to provide women a completely incision-free procedure to treat single or multiple fibroids, with very fast recovery and excellent results.  This is a huge leap forward for women who wish to preserve their uterus, avoid invasive surgery, and achieve long term reduction in heavy menstrual bleeding.”

The Sonata System uses a unique intrauterine ultrasound handpiece to locate and target the individual fibroids. Radiofrequency energy is delivered to shrink the fibroid and reduce symptoms.  The Sonata Treatment is a breakthrough alternative to hysterectomy and myomectomy, and can treat a wide range of fibroid types, sizes, and locations.  The fibroids are treated from inside the uterus, so the Sonata Treatment requires no incisions, no tissue is surgically removed, and the uterus is preserved.  Clinical studies demonstrate that nearly 90 percent of women showed a reduction in menstrual bleeding at three months and 95 percent with a reduction at 12 months.  More than 50 percent of women return to normal activities the next day.  Additionally, 94 percent of patients were satisfied at two and three years after the procedure.

“Dr. Greenberg has long been a pioneer in offering effective new treatments to women, and we are excited he and Brigham and Women’s Faulkner Hospital are offering the Sonata Treatment for women with symptomatic fibroids.  Invasive surgery can be a major deterrent to those who would otherwise seek treatment.  The Sonata System offers an alternative to not only hysterectomy and myomectomy but provides an option for those women that are not satisfied with their medical management or simply watchful waiting,” said Chris Owens, President and CEO of Gynesonics.  “We look forward to hearing more from Dr. Greenberg and his patients about the life changing impact created by the Sonata Treatment.”

For more information on the Sonata Treatment and to watch patient testimonials, please visit www.sonatatreatment.com.

About Brigham and Women’s Faulkner Hospital

Brigham and Women’s Faulkner Hospital (BWFH) is a 171-bed non-profit, community teaching hospital located in Jamaica Plain, just 3.4 miles from the Longwood medical area, and across the street from the Arnold Arboretum. Founded in 1900, BWFH has a long history of meeting the health care needs of the residents of southwest Boston and surrounding suburbs.  BWFH offers comprehensive medical, surgical and psychiatric care as well as complete emergency, ambulatory and diagnostic services. The largest inpatient services are internal medicine, cardiology, psychiatry, pulmonary, orthopedics, gastroenterology and general/GI surgery.

BWFH also has full accreditation from The Joint Commission. The Joint Commission accredits and certifies more than 15,000 health care organizations and programs in the United States and their accreditation and certification is recognized nationwide as a symbol of quality that reflects an organization’s commitment to meeting certain performance standards.

With more than 1,600 full and part time employees helping to meet the growing demand for medical services, Brigham and Women’s Faulkner Hospital and Brigham and Women’s Hospital surgical staff are now performing close to 11,000 surgical procedures a year.

About Sonata System

The Sonata System uses radiofrequency energy to ablate fibroids under real time intrauterine sonography guidance.  The Sonata System, including the SMART Guide, enables the operator to target fibroids and optimize ablations within them.  The Sonata system’s design provides a straightforward, transcervical access for a uterus-preserving, incision-free fibroid treatment.  This intrauterine approach is designed to avoid the peritoneal cavity.  The Sonata System is CE marked and is approved for sale in the European Union and the United States.

About Gynesonics

Gynesonics is a women’s healthcare company focused on advancing women’s health, by developing minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications.  Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.  Gynesonics headquarters is in Redwood City, CA.  For more information, go to www.gynesonics.com.

Company Contacts:

Rich Lanigan

VP,Global Commercialization

Gynesonics

rlanigan@gynesonics.com

001 (650)216-3860

Media Contacts:

Joanne Tedesco

Dresner Corporate Services

jtedesco@Dresnerco.com

001 (573)355-7855